Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Cerevel Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tavapadon

            Therapeutic Area: Neurology Product Name: PF-06649751

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The Phase 3 program will evaluate the efficacy, safety and tolerability of fixed doses (TEMPO-1) and flexible doses (TEMPO-2) of tavapadon.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVL-865

            Therapeutic Area: Neurology Product Name: CVL-865

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            The randomized, double-blind, placebo-controlled, parallel group Phase 2 study will assess the efficacy, safety and tolerability profile of CVL-865 as an adjunctive treatment in patients with drug-resistant focal onset seizures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVL-231

            Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: PIPE

            Deal Size: $445.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 30, 2020

            Details:

            Upon completion of the business combination, the net proceeds will be used to advance development of Cerevel Therapeutics’ diverse neuroscience pipeline, including potential treatments for schizophrenia, epilepsy, and Parkinson’s diseas.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Recipient: Cyclica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 27, 2020

            Details:

            Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVL-936

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of CVL-936 in healthy volunteers ages 18 to 50.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tavapadon

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020

            Details:

            Studies to enroll approximately 1,200 patients to determine effectiveness of tavapadon across the full spectrum of early- and late-stage parkinson’s.